Gsk (GSK) Debt Ratio (2009 - 2026)
Gsk (GSK) posted Debt Ratio of 0.29 for Q4 2025, up 1.67% on a QoQ basis from 0.29 in Q4 2024, and up 1.67% year-over-year from 0.29 in Q4 2024.
Gsk (GSK) has 10 years of Debt Ratio data on file, last reported at 0.29 in Q4 2025.
- In Q4 2025, Debt Ratio rose 1.67% year-over-year to 0.29; the TTM figure through Dec 2025 stood at 0.08 (up 17.4% YoY), while the FY2025 annual figure was 0.29, up 1.67% from the prior year.
- Debt Ratio improved to 0.29 in Q4 2025, from 0.29 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.31 in Q4 2023 and bottomed at 0.27 in Q4 2021.
- A 5-year average of 0.29 and a median of 0.29 in 2025 frame the typical range for Debt Ratio.
- Annual changes were most pronounced in 2021 — Debt Ratio decreased 9.38% — and 2022, when it gained 11.79%.
- Year by year, Debt Ratio stood at 0.27 in 2021, then climbed by 11.79% to 0.3 in 2022, then gained by 0.16% to 0.31 in 2023, then decreased by 6.59% to 0.29 in 2024, then climbed by 1.67% to 0.29 in 2025.
- The last three Debt Ratio figures came in at 0.29 (Q4 2025), 0.29 (Q4 2024), and 0.31 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 0.37 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 0.27 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 0.47 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 0.38 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 0.62 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 0.39 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.31 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 0.51 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 0.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.31 |
| Dec 31, 2025 | -0.33 |
| Sep 30, 2025 | -0.33 |
| Jun 30, 2025 | -0.35 |
| Mar 31, 2025 | -0.37 |
| Dec 31, 2024 | 0.29 |
| Sep 30, 2024 | -0.33 |
| Jun 30, 2024 | -0.34 |
| Mar 31, 2024 | -0.36 |
| Dec 31, 2023 | 0.31 |
| Sep 30, 2023 | -0.35 |
| Jun 30, 2023 | -0.35 |
| Mar 31, 2023 | -0.38 |
| Dec 31, 2022 | 0.30 |
| Sep 30, 2022 | -0.43 |
| Jun 30, 2022 | -0.27 |
| Mar 31, 2022 | -0.32 |
| Dec 31, 2021 | 0.27 |
| Sep 30, 2021 | -0.33 |
| Jun 30, 2021 | -0.33 |
| Mar 31, 2021 | -0.36 |
| Dec 31, 2020 | 0.30 |
| Jun 30, 2020 | -0.36 |
| Mar 31, 2020 | -0.35 |
| Dec 31, 2019 | 0.31 |
| Sep 30, 2019 | -0.36 |
| Jun 30, 2019 | -0.45 |
| Mar 31, 2019 | -0.46 |
| Dec 31, 2018 | 0.45 |
| Sep 30, 2018 | -0.52 |
| Jun 30, 2018 | -0.52 |
| Mar 31, 2018 | -0.34 |
| Dec 31, 2017 | 0.28 |
| Sep 30, 2017 | -0.33 |
| Jun 30, 2017 | -0.30 |
| Mar 31, 2017 | -0.33 |
| Dec 31, 2016 | 0.32 |
| Sep 30, 2016 | -0.34 |
| Jun 30, 2016 | -0.34 |
| Mar 31, 2016 | -0.29 |
| Dec 31, 2015 | -0.29 |
| Sep 30, 2015 | -0.28 |
| Jun 30, 2015 | -0.27 |
| Mar 31, 2015 | -0.26 |
| Dec 31, 2014 | -0.39 |
| Sep 30, 2014 | -0.34 |
| Jun 30, 2014 | -0.40 |
| Mar 31, 2014 | -0.39 |
| Dec 31, 2013 | -0.39 |
| Sep 30, 2013 | -0.38 |
| Jun 30, 2013 | -0.41 |
| Mar 31, 2013 | -0.40 |
| Dec 31, 2012 | 0.12 |
| Sep 30, 2012 | -0.33 |
| Jun 30, 2012 | -0.32 |
| Mar 31, 2012 | -0.29 |
| Dec 31, 2011 | 0.12 |
| Sep 30, 2011 | -0.34 |
| Jun 30, 2011 | -0.34 |
| Mar 31, 2011 | -0.35 |
| Dec 31, 2010 | -0.35 |
| Sep 30, 2010 | -0.35 |
| Jun 30, 2010 | -0.34 |
| Mar 31, 2010 | -0.34 |
| Dec 31, 2009 | -0.34 |
| Sep 30, 2009 | -0.36 |
| Jun 30, 2009 | -0.36 |
| Mar 31, 2009 | -0.39 |